Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Computers + Chemistry: Some Thoughts from ACS San Diego

Posted on March 31st, 2016 by

Chemistry

ACSSanDiego

I’ve just returned home from the 251st American Chemical Society (ACS) Meeting and Exposition in San Diego. While recovering from my jet lag, Continue reading “Computers + Chemistry: Some Thoughts from ACS San Diego” »

How Text-Mining Positively Impacts Early Stage Discovery

Posted on March 29th, 2016 by

Pharma R&D

R_D_Solutions_Blog_Image_paper_stacks_DIGITAL

Colleagues, as most of you know, text mining is the process to derive high quality structured information from unstructured text, Continue reading “How Text-Mining Positively Impacts Early Stage Discovery” »

“If you gave the same NCE to two different companies……”

Posted on March 24th, 2016 by

Pharma R&D

two-hockey-players

You might think this is the opening line for a riddle, but in fact it forms the basis of IDEA Pharma’s Productive Innovation Index (PII for short), an annual ranking of the top 30 biopharmaceutical companies Continue reading ““If you gave the same NCE to two different companies……”” »

The Privilege of Collaboration

Posted on March 22nd, 2016 by

Pharma R&D

R_D_Solutions_Blog_Image_hands_team_DIGITAL

Colleagues, collaboration is a critical factor in life science, as we all seek to move the needle in extending, and improving quality of, life. Continue reading “The Privilege of Collaboration” »

The Challenges in Treating Rare and Orphan Diseases

Posted on March 21st, 2016 by

Pharma R&D

R_D_Solutions_Blog_Image_balloons_DIGITAL

Those outside of the drug and medical research communities often do not understand the complexities and challenges in developing therapeutic treatments for diseases that Continue reading “The Challenges in Treating Rare and Orphan Diseases” »

  1. 1
  2. 42
  3. 43
  4. 44
  5. 45
  6. 46
  7. 52


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.